Apsida Life Science

Just 4 days until Alexander Coppen Finley Lenihan and I fly out to visit our #Boston team Alex and Finley will be attending the upcoming #CMOSummit360 at the Boston Park Plaza, visiting new and existing clients and contacts as well as spending time working from our US office. My aim whilst in one of my favourite cities in the world is to meet with local #Recruiters who would be interested in a new challenge and helping us grow our US footprint based from Boston. I have some very exciting meetings already planned but if we've not yet connected, please drop me a note - I'd be happy to make some time to meet for a coffee or a beer and tell you about all things Apsida Life Science and how you could be part of our exciting future! (Here's a photo from my latest visit for our Christmas party when Jamie Salmon Michael Georgiadis Charlotte Phillips and I surprised the team in December).

We're #hiring a new Clinical Research Coordinator in South Carolina. Apply today or share this post with your network.

Apsida will be attending #CMOSummit360 in Boston next week | April 7th-8th The agenda is packed with exciting opportunities to dive into the latest trends in drug development and hear from industry experts. It's an excellent chance for Alexander and Finley to connect with both new faces and familiar ones while sharing insights and discussing the future of the market. Alex and Finley are coordinating their schedules around the busy agenda and look forward to catching up with as many people as possible. They will both be touching base on Sunday before the conference to confirm availability, but in the meantime, don’t hesitate to send them a message if you'd like to arrange a coffee or a quick catch-up during the event. #apsida #cmo360 #boston

We're #hiring a new Medical Information Specialist in Basel. Apply today or share this post with your network.

We're #hiring a new Clinical Research Nurse in Lower Austria. Apply today or share this post with your network.

We're #hiring a new Regulatory Affairs Specialist in New Zealand. Apply today or share this post with your network.

Q1 Conferences Unpacked: Key Insights from the Apsida Team At Apsida, we believe in sharing knowledge, not gatekeeping it. This quarter, our team has been on the ground at industry-leading conferences, connecting with decision makers, hiring managers, and top talent across the globe. From SCOPE in Florida to DIA Europe, we’ve gathered key insights that could help refine your talent acquisition strategy for Q2. Sign up for this month’s newsletter to get the full breakdown straight to your inbox! https://lnkd.in/eRX-4HhS

We're #hiring a new Senior Clinical Research Associate in United Kingdom. Apply today or share this post with your network.

📰 🧠 Neuroscience News Updates 🧠📰 💲 Augustine Therapeutics raise oversubscribed $85 million Series A financing round to support the clinical development of AGT-100216 for the treatment of Charcot-Marie-Tooth disease. "This significant financing is a testament to the innovative medicinal chemistry that Augustine was founded on, which acts via a unique mechanism of action." - Gerhard Koenig, CEO 🔬 Contera Pharma announce that CP0014753 is ready for IND enabling studies for the treatment of Canavan disease. "The progress of the CP-102 project and specific nomination of CP0014753 to enter pre-IND studies is a significant milestone for Contera Pharma." Thomas Sager, CEO 💷 TRIMTECH Therapeutics Limited announce the closing of a $31 million seed funding round to advance pipeline of neurodegenerative disease treatments. "This oversubscribed financing round and the outstanding quality of our investor syndicate is a great endorsement of TRIMTECH’s unique approach to targeting the selective removal of aggregated proteins that underpin so many CNS diseases." Nicki Thompson, CEO 🤝 Pierandrea Muglia, MD joins Saniona as their Chief Medical Officer. "Pierandrea's extensive expertise in clinical development is invaluable as Saniona advances its pipeline for the treatment of neurological and psychiatric diseases." Thomas Feldthus, CEO 💰 SV Health Investors announce $250m fund to develop new dementia therapeutics. "SV's DDF-2 will continue the strategy of the first fund “to invest in, create and scale the best U.K. and international biotech companies that develop breakthrough, high-impact treatments in this critical field." Christian B. Jung, PhD, Managing Partner 💵 Montara Therapeutics, Inc. secures $28m in oversubscribed seed expansion to advance epilepsy program to IND, progress neurodegeneration program to development candidate, and accelerate a third undisclosed program. "This funding positions us to deliver on our mission — developing BrainOnly™ therapies, which selectively target the CNS while blocking harmful peripheral effects." Nicholas Hertz, Ph.D, Founder & CEO 🧠 Gain Therapeutics doses first patient in its Phase 1b clinical trial of GT-02287 for Parkinson's Disease. "Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with Parkinson’s disease." Gene Mack, CEO Some amazing news and developments already in the #CNS world in Q1 2025! 📧 alex.coppen@apsida.com

New Opportunity | Director, Commercial Strategy Consulting | New Jersey, USA Jon Orsbourn has just taken on an exciting new role with a leading advisory firm, supporting top biopharma organizations worldwide in maximizing brand potential through specialized insights and strategy. The firm boasts YoY growth and a global presence with 500+ employees, rapidly expanding across international locations and through several sites on the East Coast. This role is ideal for a seasoned life sciences strategy consultant with expertise in drug commercialization across the product lifecycle and major global markets. If you thrive in workshop facilitation, client engagement, and business development while leading and mentoring teams, this could be your next big move. Get in touch with Jon to learn more and submit your application | Jon.Orsbourn@apsida.com #commercialstrategy #us #lifescience #apsida